Please login to the form below

Not currently logged in
Email:
Password:

Javlor

This page shows the latest Javlor news and features for those working in and with pharma, biotech and healthcare.

NICE rejects Pierre Fabre's bladder cancer drug Javlor

NICE rejects Pierre Fabre's bladder cancer drug Javlor

NICE rejects Pierre Fabre's bladder cancer drug Javlor. Says drug received final draft 'no' because pharma company failed to prove efficacy. ... But having done so NICE nevertheless decided Javlor's high cost and 'inconclusive evidence' meant it couldn't

Latest news

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

We are industry-leading thinkers when it comes to education. We use the latest academic thinking on the psychology of behaviour...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics